CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Highlights Charles River Laboratories International, Inc. BOERSE MUENCHEN

Equities

RV6

US1598641074

Market Closed - BOERSE MUENCHEN Other stock markets 01:13:48 22/06/2024 am IST			5-day change	1st Jan Change
197.2 ^EUR	+1.08%		+0.87%	-8.07%

17/06	Charles River Laboratories, Captain T Cell Enter Manufacturing Deal	MT
17/06	Charles River Laboratories International, Inc and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Charles River Laboratories, Captain T Cell Enter Manufacturing Deal	17/06	MT
Charles River Laboratories International, Inc and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy	17/06	CI
Charles River Laboratories Opens New Contract Vivarium Space in Massachusetts	06/06	MT
The first rate cut	06/06
Charles River Laboratories Expands Access to CRADL® Contract Vivarium Space in Somerville	06/06	CI
Charles River Laboratories, Sanofi Collaborating to Develop Non-Animal Virtual Control Groups for Preclinical Trials	04/06	MT
Charles River Laboratories International, Inc. Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development	30/05	CI
Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance	09/05	MT
Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 30, 2024	09/05	CI
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Reports Q1 Adjusted EPS $2.27	09/05	MT
Stocks Down Pre-Bell Ahead of Latest Earnings Results; Asia, Europe Churn	09/05	MT
Earnings Flash (CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Posts Q1 Revenue $1.01B	09/05	MT
(CRL) CHARLES RIVER LABORATORIES INTERNATIONAL Expects Fiscal Year 2024 Adjusted EPS Range $10.90 - $11.40	09/05	MT
Charles River Laboratories International, Inc. Revises Financial Guidance for 2024	09/05	CI
FibroBiologics, Inc. Plans to Collaborate with Charles River Laboratories to Manufacture Fibroblast-Based Spheroids	25/04	CI
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing	16/04	CI
Charles River Laboratories International, Inc. and Deciphex Limited Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology	11/04	CI
Charles River Laboratories, Axovia Therapeutics Collaborate on Developing Rare Disease Gene Therapies	09/04	MT
Charles River Laboratories International, Inc. Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics	09/04	CI
Charles River Laboratories Signs Plasmid DNA Manufacturing Deal With Ship of Theseus	04/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Charles River Laboratories International, Inc. BOERSE MUENCHEN

Equities

RV6

US1598641074

Highlights

Filters